NMRA Neumora Therapeutics
- 10.990
- -0.910-7.65%
- 10.950
- -0.040-0.36%
Neumora Therapeutics News
Neumora Therapeutics Analyst Ratings
Mizuho Securities Initiates Neumora Therapeutics at Outperform With $20 Price Target
Neumora Therapeutics, Inc. (NMRA) Gets a Buy From Bank of America Securities
Analysts Are Bullish on These Healthcare Stocks: Neumora Therapeutics, Inc. (NMRA), IDEAYA Biosciences (IDYA)
Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN), Innate Pharma SA (OtherIPHYF) and Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics Analyst Ratings
RBC Capital Remains a Buy on Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics Analyst Ratings
JP Morgan Maintains Overweight on Neumora Therapeutics, Raises Price Target to $22
Neumora Therapeutics Analyst Ratings
RBC Raises Price Target on Neumora Therapeutics to $31 From $24, Keeps Outperform, Speculative Risk
Neumora Therapeutics, Inc. (NMRA) Gets a Buy From RBC Capital
Stifel Nicolaus Sticks to Its Buy Rating for Neumora Therapeutics, Inc. (NMRA)
Deutsche Bank Initiates Coverage On Neumora Therapeutics With Hold Rating, Announces Price Target of $13
Neumora Therapeutics Analyst Ratings
JP Morgan Maintains Overweight on Neumora Therapeutics, Lowers Price Target to $20
Neumora Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Sanofi (OtherSNYNF) and Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics Started With Buy Ratings at Several Wall Street Firms
RBC Initiates Neumora Therapeutics at Outperform, Speculative Risk With $24 Price Target Amid Bullish View on Lead Drug in Major Depressive Disorder
Analysis
Price Target
No Data
